A Phase I/II Trial of Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma
Phase of Trial: Phase I/II
Latest Information Update: 01 Sep 2017
At a glance
- Drugs Cabozantinib (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- 22 Sep 2016 Status changed from active, no longer recruiting to completed.
- 23 Aug 2016 Planned End Date changed from 1 May 2016 to 1 May 2017.
- 23 Aug 2016 Planned primary completion date changed from 1 May 2016 to 1 May 2017.